Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma

Journal of Histochemistry and Cytochemistry

Volumn 59, Issue 6, 2011, Pages 615-629

  Lendorf, Maria E ^a   Manon Jensen, Tina ^a   Kronqvist, Pauliina ^b   Multhaupt, Hinke A B ^a   Couchman, John R ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Breast cancer; Cell adhesion receptor; Estrogen receptor; Glycosaminoglycan; Heparan sulfate; Proteoglycan; Syndecan

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SYNDECAN 1; SYNDECAN 4; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BREAST TUMOR; CASE CONTROL STUDY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; SYNDECAN-1; SYNDECAN-4; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79960925887     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155411405057     Document Type: Article

References (76)

1. Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, Cumberledge S, Bernfield M. 2000. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet. 25:329-332.
2. Allred DC. 2010. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol. 23(suppl 2):S52-59.
3. Baba F, Swartz K, van Buren R, Eickhoff J, Zhang Y, Wolberg W, Friedl A. 2006. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Res Treat. 98:91-98.
4. Baciu PC, Goetinck PF. 1995. Protein kinase C regulates the recruitment of syndecan-4 into focal contacts. Mol Biol Cell. 6:1503-1513.
5. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, et al. 2003. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 98:474-483.
6. Bass MD, Roach KA, Morgan MR, Mostafavi-Pour Z, Schoen T, Muramatsu T, Mayer U, Ballestrem C, Spatz JP, Humphries MJ. 2007. Syndecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix. J Cell Biol. 177:527-538.
7. Beauvais DM, Ell BJ, McWorter AR, Rapraeger AC. 2009. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med. 206:691-705.
8. Beauvais DM, Rapraeger AC. 2003. Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. Exp Cell Res. 286:219-232.
9. Beauvais DM, Rapraeger AC. 2004. Syndecans in tumor cell adhesion and signalling. Reprod Biol Endocrinol. 2:3.
10. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Borresen-Dale AL, Pollack JR. 2006. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 45:1033-1040.
11. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 68:729-777.
12. Berx B, van Roy F. 2009. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol. 1(6):a003129.
13. Blackhall FH, Merry CLR, Davies EJ, Jayson GC. 2001. Heparan sulfate proteoglycans and cancer. Br J Cancer. 85: 1094-1098.
14. Burbach BJ, Friedl A, Mundhenke C, Rapraeger AC. (2003). Syndecan-1 accumulates in lysosomes of poorly differentiated breast carcinoma cells. Matrix Biol. 22:163-177.
15. Burbach BJ, Ji Y, Rapraeger AC. 2004. Syndecan-1 ectodomain regulates matrix-dependent signaling in human breast carcinoma cells. Exp Cell Res. 300:234-247.
16. Chambers AF, Groom AC, MacDonald IC. 2002. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2:563-572.
17. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et al. 2006. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 10:529-541.
18. Choi S, Lee H, Choi JR, Oh ES. 2010. Shedding: towards a new paradigm of syndecan function in cancer. BMB Rep. 43:305-310.
19. Couchman JR. 2003. Syndecans: proteoglycan regulators of cellsurface microdomains? Nat Rev Mol Cell Biol. 4:926-937.
20. Couchman JR. 2010. Transmembrane signalling proteoglycans. Annu Rev Cell Dev Biol. 26:89-114.
21. David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H. 1992. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol. 119: 961-975.
22. Dovas A, Yoneda A, Couchman JR. 2006. PKCalpha-dependent activation of RhoA by syndecan-4 during focal adhesion formation. J Cell Sci. 119:2837-2846.
23. Echtermeyer F, Streit M, Wilcox-Adelman S, Saoncella S, Denhez F, Detmar M, Goetinck P. 2001. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest. 107:R9-R14.
24. Elkin M, Cohen I, Zcharia E, Orgel A, Guatta-Rangini Z, Peretz T, Vlodavsky I, Kleinman HK. 2003. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res. 63:8821-8826.
25. Elston CW, Ellis IQ. 1991. Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:403-410.
26. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M. 2000. Shedding of syndecan-1 and -4 ectodomains is regulated by
27. multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol. 148:811-824.
28. Fjeldstad K, Kolset SO. 2005. Decreasing the metastatic potential in cancers: targeting the heparan sulfate proteoglycans. Curr Drug Targets. 6:665-682.
29. Göte M, Kersting C, Ruggiero M, Tio J, Tulusan AH, Kiesel L, Wfing P. 2006. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res. 26:621-627.
30. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell. 100:57-70.
31. Harvey JM, Clark GM, Osborne CK, Allred DC. 1999. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474-1481.
32. Horowitz A, Murakami M, Gao Y, Simons M. 1999. Phosphatidylinositol-4,5-bisphosphate mediates the interaction of syndecan-4 with protein kinase C. Biochemistry. 38:15871-15877.
33. Jayson GC, Vives C, Paraskeva C, Schofield K, Coutts J, Fleetwood A, Gallagher JT. 1999. Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma. Int J Cancer. 82:298-304.
34. Jensen EV, Jordan VC. 2003. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 9:1980-1989.
35. Kamangar F, Dores GM, Anderson WF. 2006. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137-2150.
36. Kokenyesi R, Bernfield M. 1994. Core protein structure and sequence determine the site and presence of heparan sulfate and chondroitin sulfate on syndecan-1. J Biol Chem. 269:12304-12309.
37. Kousidou OC, Berdiaki A, Kletsas D, Zafiropoulos A, Theocharis AD, Tzanakakis GN, Karamanos NK. 2008. Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol. 2:223-232.
38. Lambaerts K, Wilcox-Adelman SA, Zimmermann P. 2009. The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr Opinion Cell Biol. 21:662-669.
39. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C. 2004. Prognostic value of syndecan-1 expression in breast cancer. Oncology. 67:11-18.
40. Lim ST, Longley RL, Couchman JR, Woods A. 2003. Direct binding of syndecan-4 cytoplasmic domain to the catalytic domain of protein kinase C alpha (PKC alpha) increases focal adhesion localization of PKC alpha. J Biol Chem. 278:13795-13802.
41. Lögren L, Sahlin L, Jiang S, Von Schoultz B, Fernstad R, Skoog L, Von Schoultz E. 2007. Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women. Anticancer Res. 27:3045-3050.
42. Longley RL, Woods A, Fleetwood A, Cowling GJ, Gallagher JT, Couchman JR. 1999. Control of morphology, cytoskeleton and migration by syndecan-4. J Cell Sci. 112:3421-3431.
43. Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, Pioud-Martigny R, Berton-Rigaud D, Bourbouloux E, Mosnier JF, et al. 2008. Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer. 98:1993-1998.
44. Maeda T, Alexander CM, Friedl A. 2004. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 64:612-621.
45. Maeda T, Desouky J, Friedl A. 2006. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene. 25:1408-1412.
46. Manon-Jensen T, Itoh Y, Couchman JR. 2010. Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J. 277:3876-3889.
47. Marotti JD, Collins LC, Hu R, Tamimi RM. 2010. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol. 23:197-204.
48. Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, Ohlenz HD, Thierauch KH, Sommer A. 2004. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer. 40:1373-1382.
49. Midwood KS, Valenick LV, Hsia HC, Schwarzbauer JE. 2004. Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. Mol Biol Cell. 15:5670-5697.
50. Morgan MR, Humphries MJ, Bass MD. 2007. Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol. 8:957-969.
51. Mullan PB, Millikan RC. 2007. Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. Cell Mol Life Sci. 64:3219-3232.
52. Mundhenke C, Meyer K, Drew S, Friedl A. 2002. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol. 160:185-194.
53. Mythreye K, Blobe GC. 2009. Proteoglycan signalling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal. 21:1548-1558.
54. Oh ES, Woods A, Couchman JR. 1997. Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C. J Biol Chem. 272:11805-11811.
55. Park H, Kim Y, Lim Y, Han I, Oh ES. (2002). Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 277:29730-29736.
56. Payne SJ, Bowen RL, Jones JL, Wells CA. 2008. Predictive markers in breast cancer: the present. Histopathology. 52:82-90.
57. Perou CM, Sølie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. 2000. Molecular portraits of human breast tumours. Nature. 406:747-752.
58. Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, Niebuhr E, Bissell MJ, Rønov-Jessen L. 2003. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol. 162:391-402.
59. Rosen PP. 2001. Rosen's breast pathology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins.
60. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. 2005. Breast cancer biomarkers. Adv Clin Chem. 40:99-125.
61. Sanderson RD. 2001. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol. 12:89-98.
62. Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A. 2005. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem. 96:897-905.
63. Saoncella S, Echtermeyer F, Denhez F, Nowlen JK, Mosher DF, Robinson SD, Hynes RO, Goetinck PF. 1999. Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. Proc Natl Acad Sci U S A. 96:2805-2810.
64. Shi SR, Imam SA, Young L, Cote RJ, Taylor CR. 1995. Antigen retrieval immunohistochemistry under the influence of pH using monoclonal antibodies. J Histochem Cytochem. 43:193-201.
65. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van de Rijn M, Jeffrey SS, et al. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 98:10869-10874.
66. Stanley MJ, Stanley MW, Sanderson RD, Zera R. 1999. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol. 112:377-383.
67. Streuli CH, Akhtar N. 2009. Signal co-operation between integrins and other receptor systems. Biochem J. 418:491-506.
68. Subramaniam DS, Isaacs C. 2005. Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol. 6:147-159.
69. Subramanian SV, Fitzgerald ML, Bernfield M. 1997. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem. 272:14713-14720.
70. Tavassoli FA. 1999. Invasive lobular carcinoma. In: FA, Tavassoli editor. Pathology of the breast. 2nd ed. Stamford, CT: Appleton Lange. p. 426-436.
71. Tokes A-M, Szasz AM, Farkas A, Toth AI, Dank M, Harsanyi L, Molnar BA, Molnar IA, Laszlo Z, Rusz Z, et al. 2009. Stromal matrix protein expression following preoperative systemic therapy in breast cancer. Clin Cancer Res. 15:731-739.
72. Vargo-Gogola T, Rosen JM. 2007. Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 7:659-672.
73. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K, Haglund C. 2001. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer. 95:1-6.
74. Wolf K, Friedl P. 2006. Molecular mechanisms of cancer cell invasion and plasticity. Br J Dermatol. 154(suppl 1):11-15.
75. Woods A, Couchman JR. 1994. Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. Mol Biol Cell. 5:183-192.
76. Xian X, Gopal S, Couchman JR. 2010. Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res. 339:31-46.